Clinical Trial Update: Safety, Tolerability, and Pharmacokinetics of Clesrovimab (MK-1654) in Infants (MK-1654-002) [Phase 1, Phase 2]

View source ↗

Summary

This phase 1/2 trial update reports safety, tolerability, and pharmacokinetics data for Clesrovimab (MK-1654) in infants with respiratory infections, including …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection
• Respiratory Tract Infection

Drugs mentioned

• Clesrovimab (clesrovimab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Respiratory Tract Infection, Respiratory Syncytial Virus | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2023-11-29